Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices 79921 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–24JB; Docket No. CDC–2024– 

0075] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled National 

Surveillance for C. auris Cases. The 

purpose of this project is to collect 

minimal pertinent information about C. 

auris cases based on the Council of State 

and Territorial Epidemiologists (CSTE) 

case definition. 

DATES: CDC must receive written 

comments on or before December 2, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0075 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. Please note: 

Submit all comments through the 

Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

National Surveillance for C. auris 

Cases—New—National Center for 

Emerging and Zoonotic Infectious 

Diseases (NCEZID), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

Candida auris (C. auris) is an 

emerging healthcare-associated fungal 

pathogen associated with high mortality 

and antifungal resistance. The incidence 

of C. auris cases has continued to 

increase globally and in the United 

States. Most cases are the result of 

healthcare transmission and have 

mortality estimates between 30–60%. C. 

auris can asymptomatically colonize the 

skin and other body sites, which 

contributes to potential spread and 

increases patients’ risk of clinical 

infections. The persistence of C. auris 

on the skin has been linked to an 

increased risk in the development of C. 

auris-related bloodstream infections in 

adults and pediatric cases. These 

clinical infections can be severe and 

invasive and are associated with high 

mortality. 

The goal of the National Surveillance 

for C. auris Cases is to monitor burden 

to guide public health action and 

ultimately prevent morbidity and 

mortality from C. auris. In coordination 

with the states/jurisdictions that submit 

data, CDC plans to share, present, and 

publish findings to the general public 

on the burden of C. auris in the United 

States. CDC requests OMB approval of 

an estimated 1,303 annual burden 

hours. There is no cost to respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

States/Jurisdictions ........................... MDB Candida auris .......................... 46 340 5/60 1,303 

Total ........................................... ........................................................... ........................ ........................ ........................ 1,303 


khammond on DSKJM1Z7X2PROD with NOTICES
79922 Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–22476 Filed 9–30–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–24–1046; Docket No. CDC–2024– 

0074] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a continuing information collection, as 

required by the Paperwork Reduction 

Act of 1995. This notice invites 

comment on a proposed information 

collection project titled National Breast 

and Cervical Cancer Early Detection 

Program (NBCCEDP) Monitoring 

Activities. This data collection is 

designed to systematically collect 

information about implementation, 

including delivery of screening and 

follow-up clinical services, and 

outcomes of the National Breast and 

Cervical Cancer Early Detection Program 

(NBCCEDP). 

DATES: CDC must receive written 

comments on or before December 2, 

2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0074 by either of the following methods: 

• Federal eRulemaking Portal: 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

www.regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(www.regulations.gov) or by U.S. mail to 

the address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; 

Telephone: 404–639–7570; Email: omb@

cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP) 

Monitoring Activities (OMB Control No. 

0920–1046, Exp. 03/31/2025)— 

Revision—National Center for Chronic 

Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

CDC is requesting a Revision of the 

information collection titled National 

Breast and Cervical Cancer Early 

Detection Program (NBCCEDP) 

Monitoring Activities (OMB Control No. 

0920–1046). The information collection 

consists of an annual NBCCEDP survey, 

baseline and annual clinic-level data 

collection, a quarterly program update 

(QPU) tool, a service delivery projection 

worksheet, and minimum data elements 

(MDEs). CDC proposes revisions to the 

Annual NBCCEDP Survey, clinic-level 

data collection tool and QPU, and 

continued use of the service delivery 

projection worksheet and MDEs with no 

changes. The number of respondents 

will increase from 70 to 71 and the total 

estimated annualized burden will 

decrease from 1,220 hours to 1,162 

hours. 

Breast and cervical cancers are 

prevalent among U.S. women. In 2021, 

the U.S. experienced 272,454 new cases 

and 42,211 deaths as a result of breast 

cancer, as well as 12,536 new cases and 

4,051 deaths as a result of cervical 

cancer. Evidence shows that deaths 

from both breast and cervical cancers 

can be avoided by increasing screening 

services—mammography, pap, and 

human papillomavirus (HPV) tests— 

among women. However, in 2021, 

approximately one quarter of adults 

were not up to date with breast and/or 

cervical cancer screening, and screening 

was underutilized among women who 

are under- or uninsured, have no regular 

source of healthcare, or who recently 

immigrated to the U.S. As a 

longstanding priority within chronic 

disease prevention, CDC focuses on 

increasing access to these cancer 

screenings, particularly among women 

who may be at increased risk. 

To improve access to cancer 

screening, Congress passed the Breast 

and Cervical Cancer Mortality 

Prevention Act of 1990 (Pub. L. 106– 

354), which directed CDC to create the 

National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP). 

The NBCCEDP currently provides 

funding to 71 recipients under ‘‘Cancer 

Prevention and Control Programs for 

State, Territorial, and Tribal 

Organizations (DP22–2202).’’ NBCCEDP 

awardees include states or their bona 

fide agents; U.S. territories; and tribes or 

tribal organizations. The purpose of 

NBCCEDP is to increase breast and 

cervical cancer screening rates among 

women residing within defined 

geographical locations (as determined 

by the funded program) who are at or 

below 250% of the federal poverty level; 

aged 50–75 years for breast cancer 


khammond on DSKJM1Z7X2PROD with NOTICES